alpha B-crystallin/HSPB2 is critical for hyperactive mTOR-induced cardiomyopathy
alpha B-crystallin/HSPB2 is critical for hyperactive mTOR-induced cardiomyopathy
复制标题
α B-晶状体蛋白/HSPB2 对于高活性 mTOR 诱发的心肌病至关重要
DOI:
10.1002/jcp.30465
复制
发表时间:
2021
影响因子:
5.6
通讯作者:
Hongbing Zhang
中科院分区:
文献类型:
--
作者:
Lianmei Wang;Fang Wanng;Kemei Liu;Caifeng Long;Yi Chen;Chunjia Li;Li Li;Fangming Liu;Xinyu Zhang;Yanling Jing;Yanan Wang;Aihua Liang;Hongbing Yan;Hongbing Zhang
Even though aberrant mechanistic target of rapamycin (mTOR) signaling is known to cause cardiomyopathy, its underlying mechanism remains poorly understood. Because augmentation ofαB‐crystallinandhspB2was presented in the cortical tubers and lymphangioleiomyomatosis of tuberous sclerosis complex patients, we deciphered the role ofαB‐crystallinand its adjacent duplicate gene,hspB2, in hyperactive mTOR‐induced cardiomyopathy. CardiacTsc1deletion (T1‐hKO) caused mouse mTOR activation and cardiomyopathy. Overexpression of αB‐crystallin and hspB2 was presented in the hearts of these mice. Knockout ofαB‐crystallin/hspB2reversed deficientTsc1‐mediated fetal gene expression, mTOR activation, mitochondrial damage, cardiomyocyte vacuolar degeneration, cardiomyocyte size, and fibrosis ofT1‐hKO mice. These cardiac‐Tsc1;αB‐crystallin;hspB2triple knockout (tKO) mice had improved cardiac function, smaller heart weight to body weight ratio, and reduced lethality compared withT1‐hKO mice. Even though activated mTOR suppressed autophagy inT1‐hKO mice, ablation ofαB‐crystallinandhspB2failed to restore autophagy in tKO mice. mTOR inhibitors suppressed αB‐crystallin expression inT1‐hKO mice and rat cardiomyocyte line H9C2. Starvation of H9C2 cells activated autophagy and suppressed αB‐crystallin expression. Since inhibition of autophagy restored αB‐crystallin expression in starved H9C2 cells, autophagy is a negative regulator of αB‐crystallin expression. mTOR thus stimulates αB‐crystallin expression through suppression of autophagy. In conclusion, αB‐crystallin and hspB2 play a pivotal role inTsc1knockout‐related cardiomyopathy and are therapeutic targets of hyperactive mTOR‐associated cardiomyopathy.